Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.

about

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.

Item

http://www.wikidata.org/entity/Q54923034

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Radioligand therapy of metasta ...... te cancer: current approaches.

@en

Radioligand therapy of metasta ...... te cancer: current approaches.

@nl

type

Item

label

Radioligand therapy of metasta ...... te cancer: current approaches.

@en

Radioligand therapy of metasta ...... te cancer: current approaches.

@nl

prefLabel

Radioligand therapy of metasta ...... te cancer: current approaches.

@en

Radioligand therapy of metasta ...... te cancer: current approaches.

@nl

P1476

Radioligand therapy of metasta ...... te cancer: current approaches.

@en

P2093

Hojjat Ahmadzadehfar

http://www.w3.org/2001/XMLSchema#string

Markus Essler

http://www.w3.org/2001/XMLSchema#string

Zool Hilmi Awang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.

P2888

s13014-018-1037-7

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1186/S13014-018-1037-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104089489

http://www.w3.org/2001/XMLSchema#string

P698

29792198

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

castration-resistant prostatic neoplasm

Anzim

P932

5966863

http://www.w3.org/2001/XMLSchema#string